Regen BioPharma logo

Regen BioPharma(OTC) RGBPP

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2016)-100%
5 Year-100%
1 Year-97%
1 Month-38%
$0.00
-58.62%
-0.00Today
Regen BioPharma last closing stock price
MetricPriceDate
Last closeUSD 0.002026-10-13
Regen BioPharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-25%USD 0.002026-10-06
1 month-38.46%USD 0.002026-09-11
3 month-60%USD 0.002026-07-15
Year to date-93.33%USD 0.022025-12-31
1 year-97.33%USD 0.052025-10-13
3 year-94.74%USD 0.022023-10-13
5 year-99.86%USD 0.872021-10-14
Since inception-100%USD 62.502016-04-21

Regen BioPharma Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$236.56K

Net Income (TTM)

-$1.19M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.59 (Low)

Price

$0.00

Volume

376,688

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.10

Estimated Earnings Date

May 11, 2026

RGBPP News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Regen BioPharma

Regen BioPharma, Inc. is focused on advancing regenerative medicine solutions in the United States. The company is engaged in the development of small molecules that modulate NR2F6, targeting cancer treatments and autoimmune conditions.

Products and Services
  • Development of small molecules for cancer treatment
  • Therapeutic approaches for autoimmune conditions
  • Research in regenerative medicine
Growth Outlook
  • Established in 2012, with a focus on innovative therapies
  • Product pipeline in early developmental phases, indicating potential for future growth
  • Commitment to advancing regenerative medicine solutions
Financial Highlights
  • Recent quarterly revenue of 59,065, showing consistent performance
  • Trailing twelve months (TTM) net income reflects ongoing investment in R&D
  • Current ratio of 0.046 indicates liquidity challenges
Regen BioPharma, Inc. operates in the biotechnology sector, with a market capitalization of approximately $70,968. The company has a unique focus on modulating NR2F6, which could lead to significant advancements in cancer and autoimmune therapies. Despite facing financial challenges, including a negative net income, the company continues to invest in research and development, positioning itself for potential future growth. The recent quarterly revenue indicates a stable performance, while the TTM data highlights the ongoing commitment to innovation in regenerative medicine. Investors may find interest in the company's long-term vision and its potential to contribute to the evolving landscape of healthcare solutions.
AI Generated • Oct 10, 2026

Industry

Biotechnology

Headquarters

La Mesa, CA 91942, US

RGBPP Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-339.81%

Net Income Margin

-501.43%

Return on Equity

19.69%

Return on Capital

N/A

Return on Assets

-412.46%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

0

Volume

376.69K

Avg. Volume

294.23K

Financials (TTM)

Gross Profit

$236.56K

Operating Income

-$803.86K

EBITDA

-$1.13M

Operating Cash Flow

-$445.25K

Capital Expenditure

$3.00

Free Cash Flow

-$445.25K

Cash & ST Invst.

$239.00

Total Debt

$924.72K

Regen BioPharma Performance Analysis

Regen BioPharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-09-300.5%
Q12025-12-31-0.5%
Q22026-03-31N/A
Q32026-06-30N/A
Regen BioPharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-09-30-107.1%
Q12025-12-3133.1%
Q22026-03-31155.7%
Q32026-06-30-118.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q3 2026YOY CHG

Revenue

$59.07K

+0.0%

Gross Profit

$59.07K

+0.0%

Gross Margin

100.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

1

N/A

Net Income

-$637.79K

-281.2%

EBITDA

$33.28K

+137.3%

Quarterly Fundamentals

Name
Q3 2026YOY CHG

Total Cash

$239.00

-86.4%

Total Debt

$924.72K

-10.8%

Accounts Receivable

$287.15K

+62.1%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$924.72K

-10.8%

Return on Assets

-4.12%

N/A

Return on Invested Capital

13.68%

N/A

Free Cash Flow

-$24.07K

+57.0%

Operating Cash Flow

-$24.07K

+57.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
APLIFAppili Therapeutics Inc.
$0.00+0.00%
ADXSAyala Pharmaceuticals, Inc.
$0.60+0.00%
AGNPFGrey Matters Health Inc.
$0.25-16.10%
ZLDAFZelira Therapeutics Limited
$0.26+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
BACBank of America
$49.97-7.40%
CRWVCoreWeave
$66.60-14.41%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$40.75+8.90%
SOFISoFi Technologies
$14.20-6.83%

Questions About RGBPP

What is the current price of Regen BioPharma?

Regen BioPharma is trading at $0.00 per share.

What is the 52-week range for Regen BioPharma?

Over the past 52 weeks, Regen BioPharma has traded between $0.00 and $0.10.

How much debt does Regen BioPharma have?

Regen BioPharma total debt is unavailable.

How much cash does Regen BioPharma have on hand?

Regen BioPharma does not have cash on hand data available.

What is Regen BioPharma’s dividend yield?

Regen BioPharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.